Host Genetics and Viral Diversity: Report from a Global HIV Vaccine Enterprise Working Group

Andrew Mcmichael,Francine Mccutchan,The

doi:10.1038/npre.2010.4797.1

Andrew Mcmichael, Francine Mccutchan + Show 1 more

Open Access

https://doi.org/10.1038/npre.2010.4797.1

Copy DOI

Abstract

AbstractThe Global HIV Vaccine Enterprise convened a workshop in September 2009 to discuss human and viral genetic variation and its impact on future directions for HIV vaccine research and development. The formidable challenges presented by virus and host genetic variability are interrelated and complicate vaccine development. HIV vaccine researchers need to develop innovative approaches that will facilitate addressing these questions in novel ways.

Highlights

The Global HIV Vaccine Enterprise convened a workshop in September 2009 to discuss human and viral genetic variation and its impact on future directions for HIV vaccine research and development
The mechanisms underlying this phenomenon are not fully understood, but for the B27, B51 and B57/58 families it is probable that HLA-restricted T cells play an important role by targeting conserved epitopes in the HIV-1 p24 protein[6,7]
Genome-wide association studies (GWAS) have identified a variant in HLA-C, the -35 SNP that is associated with lower viral load, its mechanism of action is not clear[14]

Summary

Introduction

The Global HIV Vaccine Enterprise convened a workshop in September 2009 to discuss human and viral genetic variation and its impact on future directions for HIV vaccine research and development. The formidable challenges presented by virus and host genetic variability are interrelated and complicate vaccine development. HIV vaccine researchers need to develop innovative approaches that will facilitate addressing these questions in novel ways

Challenges and Opportunities

Conclusions